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Summary
Background Becocalcidiol is a vitamin D3 analogue which has not caused hyper-
calcaemia or significant irritation in preclinical trials.
Objectives To evaluate the efficacy and safety of two dosing regimens of becocalcidiol
ointment (low dose = 75 lg g)1 once daily for 8 weeks; high dose = 75 lg g)1
twice daily for 8 weeks) in the treatment of plaque-type psoriasis.
Methods One hundred and eighty-five subjects with chronic plaque-type psoriasis
affecting 2–10% of their body surface area took part in a multicentre, double-
blind, parallel-group, vehicle-controlled, randomized controlled trial comparing
topical application of placebo, becocalcidiol 75 lg g)1 once daily (low dose) or
becocalcidiol twice daily (high dose) for 8 weeks. Main outcomes included Phy-
sician’s Static Global Assessment of Overall Lesion Severity (PGA) score; Psoriasis
Symptom Severity (PSS) score; adverse events; and laboratory assessment.
Results In the intent-to-treat population at week 8, high-dose becocalcidiol
was statistically superior to vehicle [P = 0Æ002; 95% confidence interval (CI)
6Æ7–32Æ2], with 16 of 61 (26%) subjects achieving a PGA score of clear or
almost clear. Greater improvement in PSS score was seen with high-dose becocal-
cidiol than with vehicle, but this result did not quite achieve statistical signifi-
cance (P = 0Æ052; 95% CI –16Æ2 to 0Æ1). In all groups, therapy was safe and well
tolerated, with fewer subjects experiencing irritation than is reported in studies
using calcipotriol.
Conclusions Treatment with high-dose topical becocalcidiol for 8 weeks led to
almost or complete clearing of moderate plaque-type psoriasis in over a quarter
of patients. Therapy was safe and well tolerated.
Psoriasis is a chronic, hyperproliferative, inflammatory disease
of the skin, characterized by the formation of well-demarca-
ted, erythematous plaques typically surmounted by a silver-
white thick scale. Involvement may range from one small
lesion on an extremity to generalized involvement of most of
the skin surface.
While the exact mechanisms underlying the disease are still
not completely clear, it is known that immune mechanisms,
mediated by cytokines, eventually lead to hyperproliferation of
keratinocytes, which manifests clinically as the scaly plaques
characteristic of the disease.
For nearly 20 years, topical vitamin D and its analogues have
been known to be effective in treatment of psoriasis. Active
vitamin D3 inhibits keratinocyte proliferation, modulates
epidermal differentiation, and has anti-inflammatory effects.1–3
In the U.S.A., only one analogue is currently approved for
clinical use—calcipotriol. It has been demonstrated to be effect-
ive in treatment of psoriasis.4–8 However, there are reports
of hypercalcaemia and hypercalciuria when used in high
doses.9–12 This could limit its usefulness in young or small
patients and in those with extensive involvement. In addition,
calcipotriol causes local skin irritation in approximately
15–25% of patients.13–16 This lesional or perilesional irritation
develops within the first few weeks of therapy and consists of a
burning or stinging sensation; in more severe cases, it manifests
as erythema or scaling.13 The ideal topical vitamin D analogue
would be highly effective, would not cause hypercalcaemia
even when used in large amounts, and would not cause local
skin irritation.
This study examines a new vitamin D3 analogue, 2-
methylene-19-nor-20(S)-1a-hydroxy-bishomopregnacalciferol
(2MbisP), now known as becocalcidiol (QRX-101; QuatRx,
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Ann Arbor, MI, U.S.A.). In preclinical models, becocalcidiol
did not appear to cause hypercalcaemia.17 Prior clinical studies
with becocalcidiol ointment at concentrations up to 25 lg g)1
once daily have also supported a lack of hypercalcaemia
(unpublished data). These studies have demonstrated excellent
safety and tolerability, with trends toward improved efficacy
at higher concentrations studied (5–25 lg g)1). This study
was designed to evaluate the safety and efficacy of becocalci-




This was a randomized, double-blind, parallel-group, multicen-
tre, vehicle-controlled study conducted in subjects with chronic
plaque-type psoriasis affecting 2–10% of their body surface area
(BSA). After a wash-out period of up to 30 days, eligible sub-
jects were randomized to one of the following three treatment
groups: (i) becocalcidiol 75 lg g)1 twice daily (henceforth
referred to as high-dose becocalcidiol); (ii) vehicle applied
in the morning and becocalcidiol 75 lg g)1 applied at bed-
time (henceforth referred to as low-dose becocalcidiol); and
(iii) vehicle twice daily.
The protocol and informed consent documents were
reviewed and approved by the Institutional Review Board for
each investigational centre participating in the study.
Patients
The study was conducted at 12 study sites—both academic
and private centres—in the U.S.A. Of 324 male and female
subjects screened, 185 subjects were randomized. The study
was initiated in September 2004 and completed in March
2005. Subjects were aged 18 years and older and had plaque-
type psoriasis affecting 2–10% of their BSA at screening. Psori-
asis was of a severity appropriate for topical therapy. Subjects
were evaluated by medically trained personnel with experience
in treating psoriatic lesions. Subjects refrained from topical
psoriasis treatments for 2 weeks and from systemic treatments
and ultraviolet radiation therapy for 4 weeks. Use of biologic
agents or monoclonal antibodies in the last 6 months was pro-
hibited. Subjects could not have taken a vitamin D supplement
exceeding 400 IU per day or a calcium supplement exceeding
1200 mg per day within the last 30 days. Pregnant or nursing
women, subjects with significant medical problems, and those
with sensitivity to study drug were excluded. Women of
childbearing age had to have a negative urine pregnancy test
result on day 1 and be willing to use an acceptable method of
birth control during the study.
Study medication and blinding
Subjects were randomized 1 : 1 : 1 to vehicle, low-dose beco-
calcidiol and high-dose becocalcidiol groups. Becocalcidiol
and vehicle were supplied by Dow Pharmaceutical Sciences
(Petaluma, CA, U.S.A.) in identical containers and were identi-
cal in appearance. Subjects were assigned kits containing study
medication; subjects were randomized by kit number and
were assigned kits in sequential order from the available kits
at each site. Subjects, study personnel and investigators were
blinded as to the contents of the tubes.
Study medication was applied twice daily (once in the
morning and once at bedtime) to all psoriasis plaques (both
target plaques and nontarget plaques) for 8 weeks or until
clearing [Physician’s Static Global Assessment of Overall Lesion
Severity (PGA) = 0]. The amount of study medication applied
was up to 4 g of ointment per application (maximum 8 g of
ointment daily; maximum 56 g of ointment per week). Sub-
jects could take multiple vitamins including up to 400 IU of
vitamin D and ⁄or up to 1200 mg of calcium daily during the
study. Subjects could use tar shampoo to treat scalp psoriasis
but could not use any other antipsoriasis medications during
the study. If a subject took any immunosuppressive drugs,
other psoriatic therapies, lithium, hydroxychloroquine or bio-
logic agents during the study, the subject was discontinued
from the study.
Assessments
Subjects were seen and evaluated at the screening and baseline
(day 0) visits, and at weeks 2, 4 and 8. Assessments of effi-
cacy and adverse events (AEs) were made at each visit.
The primary efficacy measurements included the PGA score
and the Psoriasis Symptom Severity (PSS) score. The PGA,
assessing all of the subject’s plaques, was determined at each
visit, using a six-point scale (0, clear; 1, almost clear; 2, mild;
3, moderate; 4, severe; 5, very severe). At baseline, PGA had
to be at least 3 (moderate). For analysis purposes, this assess-
ment was dichotomized into success vs. failure, with success
being defined as a PGA score of 0 or 1. The PGA was a static
assessment of the appearance of the psoriasis at the time of
the assessment and was not a comparison with any previous
assessment. The dichotomized outcome at week 8 was a
primary efficacy parameter.
At screening, two to four target plaques were selected for
individual study assessments; these could not be on the face
or scalp. At each visit, a PSS score was determined for each of
the target plaques. The PSS was calculated as a sum of scores
for erythema, induration and scaling. A five-point scale (0–4)
was used for each variable so that the PSS could range from 0
(plaque completely clear) to 12 (severe erythema, induration
and scaling). At baseline, each target plaque had a PSS score of
at least 7 and no individual symptom score (erythema, indura-
tion or scaling) of < 2. A mean of the PSS values from the
two to four target plaques was used for analysis purposes. The
percentage change in mean PSS from the baseline visit to week
8 was a primary efficacy parameter. The PSS was selected over
the Psoriasis Area and Severity Index (PASI) because of the
limited area of disease in this patient group (< 10% BSA). In
patients with limited disease, the PASI is not recommended as
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a clinical evaluation tool.18 Erythema, scaling and induration
are severity hallmarks of individual lesions; these are measured
in both the PSS and the Total Sign ⁄Severity Score.19
The secondary efficacy variables were the dichotomized PGA
at weeks 2 and 4; ordinal PGA at weeks 2, 4 and 8; percentage
change from baseline mean PSS at weeks 2 and 4; mean ordinal
PSS at weeks 2, 4 and 8; individual symptom scores (erythema,
induration and scaling) at weeks 2, 4 and 8; and BSA involve-
ment at weeks 2, 4 and 8.
Safety was assessed by monitoring and recording of all AEs
throughout the study period. Laboratory evaluations, including
serum calcium, serum phosphorus, serum parathyroid hor-
mone and 24-h urine calcium, were performed at the screening
visit and at weeks 2, 4 and 8 ⁄final treatment (or early termin-
ation) visits. All women of childbearing potential took a urine
pregnancy test at baseline and week 8 ⁄early termination visits.
Subjects were queried about dosing compliance at each
visit. Any subject who missed more than three consecutive
days (six consecutive doses) of dosing was discontinued from
the study due to lack of compliance.
Statistical analysis
Efficacy analyses were performed using three study popula-
tions. The intent-to-treat (ITT) population was utilized for all
efficacy analyses. Subjects evaluable for the ITT analysis popu-
lation had to be randomized and to have received at least one
dose of study medication. The per protocol (PP) population
was a second subset population utilized for all efficacy analy-
ses and included subjects who completed 8 weeks of therapy.
Excluded were those subjects who prematurely discontinued
treatment for reasons other than worsening of their psoriasis,
who did not complete the week 8 efficacy evaluation, or who
had noteworthy study protocol violations. The safety popula-
tion consisted of subjects who were utilized for all safety ana-
lyses, were randomized to study medication, and received at
least one dose of medication.
Each primary efficacy parameter was compared between
each active treatment and its vehicle control using pairwise
tests. The dichotomized PGA was analysed using Cochran–
Mantel–Haenszel (CMH) analysis stratifying an investigational
site and a binomial confidence interval (CI). The percentage
change from baseline in PSS score was assessed with analysis
of variance (ANOVA). Statistical analysis of discrete secondary
parameters employed CMH analysis, stratified for investiga-
tional site. Statistical analysis of continuous secondary para-
meters employed ANOVA.
The assessment of safety was based on the frequency of AEs
with other safety data summarized as appropriate. Safety data
are summarized using descriptive statistics.
The study was powered based on the analysis of the dicho-
tomized PGA at week 8. Using a two-sided v2 approximation
to the CMH test, assuming type I error is 5%, the sample sizes
of 50 PP subjects per treatment group yielded 80% power to
detect a treatment difference in success rates of 30% if the
active treatment was assumed to have 60% success.
Results
Of the 185 subjects who were randomized, 60 were random-
ized to vehicle, 61 to high-dose becocalcidiol and 64 to low-
dose becocalcidiol. Of these, 158 (85%) completed the study
without major protocol violations; the percentage of subjects
who completed the study was comparable across groups (86%
and 84% for the low- and high-dose becocalcidiol groups,
respectively, compared with 87% in the vehicle group). The
patients’ baseline characteristics were similar across treatment
groups (Table 1).
A total of 23 subjects discontinued the study (Table 2).
Four subjects completed the study but had major protocol vio-
lations. One subject did not have a complete 2-week washout
period before enrolment. One subject missed 17 consecutive
doses of drug due to shipping delay (subject was allowed to
proceed with study). One subject missed 16 consecutive doses
of study drug, while the final subject missed 36 consecutive
doses of study drug.
Table 3 summarizes the number of randomized subjects
excluded from the PP efficacy analysis. Reasons for excluding
subjects from the analysis were generally comparable across
groups.
Table 1 Baseline characteristics
Disposition Vehicle (n = 60)
Becocalcidiol
High dose (n = 61) Low dose (n = 64)
Age, mean (range), years 53Æ1 (23–76) 46Æ4 (19–78) 47Æ6 (22–83)
Sex, M ⁄F, n 27 ⁄33 35 ⁄26 43 ⁄21
Weight, mean (range), kg 85Æ6 (48Æ0–150Æ3) 85Æ6 (46Æ3–135Æ5) 86Æ7 (54Æ4–148Æ0)
Psoriasis duration, mean (range), years 17Æ4 (0Æ6–57) 18Æ6 (0Æ7–65) 16Æ0 (0Æ5–51)
Baseline PGA score, mean (range) 3Æ2 (3–4) 3Æ1 (3–4) 3Æ3 (3–4)
Baseline PSS score, mean (range) 8Æ2 (7Æ0–10Æ3) 7Æ9 (4Æ7–11Æ0) 8Æ1 (6Æ5–12Æ0)
Baseline percentage BSA involved, mean (range) 5Æ43 (2Æ0–13Æ0) 4Æ8 (2Æ0–10Æ0) 5Æ9 (2Æ0–14Æ0)
PGA, Physician’s Static Global Assessment of Overall Lesion Severity; PSS, Psoriasis Symptom Severity; BSA, body surface area.
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Efficacy
In the PP population, the dichotomized PGA scores at week 8
indicated a successful outcome for three of 52 (6%), 11 of 55
(20%) and 16 of 51 (31%) subjects in the vehicle, low-dose
and high-dose becocalcidiol groups, respectively. Both high-
dose and low-dose becocalcidiol groups were statistically
superior to vehicle [P < 0Æ001 (95% CI 11Æ4–39Æ8) and
P = 0Æ027 (95% CI 1Æ9–26Æ6), respectively]. There was no
statistically significant difference between the high-dose and
low-dose becocalcidiol groups. For the ITT population, the
dichotomized PGA scores at week 8 indicated a successful out-
come for four of 59 (7%), 11 of 64 (17%) and 16 of 61
(26%) subjects in the vehicle, low-dose and high-dose beco-
calcidiol groups, respectively. The high-dose becocalcidiol
group was statistically superior to vehicle (P = 0Æ002; 95% CI
6Æ7–32Æ2). The low-dose group approached, but did not
achieve, significant superiority to vehicle (P = 0Æ078; 95% CI
–0Æ8 to 21Æ7) (Fig. 1).
In the PP population, the mean percentage change in PSS
score from baseline to week 8 (or end of treatment) was
–41Æ37, –44Æ35 and –52Æ40 in the vehicle, low-dose and
high-dose becocalcidiol groups, respectively. The high-dose
becocalcidiol group was statistically superior to vehicle
(P = 0Æ005; 95% CI –18Æ3 to –3Æ2). There was no signifi-
cant difference between the low-dose and vehicle groups
(P = 0Æ570; 95% CI –9Æ6 to 5Æ3). For the ITT population, the
mean percentage change in PSS score was –39Æ99, –40Æ20 and
–48Æ48 in the vehicle, low-dose and high-dose becocalcidiol
groups, respectively. The high-dose becocalcidiol group was
marginally superior to vehicle, but this result did not quite
achieve statistical significance (P = 0Æ052; 95% CI –16Æ2 to
0Æ1) (Fig. 2).
Secondary efficacy measures supported the findings
observed in the primary efficacy measures over time, namely
that there was a possible trend towards outcomes of greater
success with high-dose becocalcidiol.
Table 2 Disposition of patients
Disposition









Treated 60 61 64




Discontinued 7 8 8
Reason for discontinuation
Adverse event 0 (0) 3 (5) 2 (3)
Lost to follow-up 1 (2) 3 (5) 3 (5)
Protocol violation 0 (0) 1 (2) 0 (0)
Subject request 3 (5) 1 (2) 2 (3)
Worsening of condition 2 (3) 0 (0) 1 (2)
Other 1 (2) 0 (0) 0 (0)
Table 3 Subjects excluded from efficacy
analysis—per protocol population
Reasons not included in analysis









More than six consecutive missed doses 4 (7) 1 (2) 2 (3)
Completed but major protocol violations 1 (2) 2 (3) 1 (2)
Did not complete, condition not worse,
and PGA not zero at week 8 ⁄ET
5 (8) 8 (13) 7 (11)
Did not complete, discontinued due to
‘worsening of condition’, and week 8 ⁄ET
psoriasis assessments not completed
1 (2) 0 (0) 1 (2)




























Fig 1. Percentage of subjects achieving success as measured by
Physician’s Static Global Assessment of Overall Lesion Severity
(PGA) = 0 or 1 (intent-to-treat population). For high-dose group and
low-dose group vs. vehicle, P = 0Æ002, 95% confidence interval (CI)
6Æ7–32Æ2 and P = 0Æ078, 95% CI –0Æ8 to 21Æ7, respectively.
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Safety
Adverse events
Becocalcidiol therapy was well tolerated. Sixty-eight (37%) of
the 185 patients had AEs, which were mostly mild or moder-
ate. Three subjects had a serious AE but none of these events
was related to the study medication (abdominal pain, pneu-
monia, and foot fracture). Five subjects were withdrawn from
the study due to treatment-related AEs (application site burn-
ing, elevated liver enzymes, allergic dermatitis, contact derma-
titis with pruritus, and worsening of psoriasis): three subjects
in the high-dose group and two subjects in the low-dose
group. The most frequently occurring AE was nasopharyngitis
which was reported in seven vehicle subjects, three low-dose
subjects and one high-dose subject. Drug-related AEs were
reported in two (3%) vehicle-treated subjects, three subjects
(5%) in the low-dose and eight subjects (13%) in the high-
dose becocalcidiol groups. Nine subjects reported skin-related
AEs, of which eight were thought to be possibly or probably
related to the study drug. These included pruritus, rashes
thought by the investigator to be consistent with allergic
dermatitis or contact dermatitis, worsening of psoriasis, rash
and urticaria. No allergic or patch testing was performed on
any subjects to determine whether becocalcidiol caused an
allergic reaction. In the low-dose becocalcidiol group, one
subject (2%) developed allergic dermatitis and another (2%)
developed rash. In the high-dose group, one subject (2%)
developed contact dermatitis, two (3%) developed pruritus,
one (2%) developed urticaria, and one (2%) had worsening























Fig 2. Mean percentage change in Psoriasis Symptom Severity (PSS)
score from baseline by visit (intent-to-treat population). For high-dose
group vs. vehicle, P = 0Æ052, 95% confidence interval –16Æ2 to 0Æ1.


















































































Fig 3. Mean laboratory values over the course of the study.
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Laboratory findings
Mean and median clinical laboratory values were generally
comparable across groups at all laboratory measurement inter-
vals. There were no clinically significant findings in serum or
urinary calcium, serum or urinary phosphorus, serum parathy-
roid hormone level or urinary NTX-telopeptide (Fig. 3). Eleva-
ted glucose levels were frequently observed in all groups
throughout the study. Fourteen subjects with a history of dia-
betes (type 1 and type 2) were enrolled in the study. None of
the subjects developed hypercalcaemia.
Discussion
This phase IIb study demonstrates the effectiveness of becocal-
cidiol in treatment of mild to moderate plaque-type psoriasis.
Over 25% of patients applying becocalcidiol twice daily
experienced almost or complete clearing of their psoriasis
(PGA = 0 or 1). Twice daily application of becocalcidiol also
induced greater improvement in the individual plaque severity
scoring, as assessed by the PSS, compared with vehicle.
Localized burning and pruritus are the major complaints
associated with calcipotriol, and in studies of calcipotriol, up
to 25% of patients complain of irritation.16 In our study,
localized burning was seen in only one subject applying
becocalcidiol twice daily. Two subjects (3%) in the high-
dose group complained of pruritus. Other skin-related side-
effects were also rare. In general, the drug was very well
tolerated. No subjects developed hypercalcaemia or hypercal-
ciuria. No significant increase in either blood or urine bio-
chemical parameters related to calcium metabolism was
observed with application of up to a maximum of 56 g of
ointment per week. Doses greater than 100 g per week were
not used in this study, so we are unable to say whether this
drug is more or less likely than calcipotriol to produce
hypercalcaemia at high doses. Our results demonstrate that
topical becocalcidiol (75 lg g)1) applied twice daily is an
effective, safe and well-tolerated therapy for treatment of
plaque-type psoriasis, with at least a 66% reduction in the
frequency of cutaneous side-effects as compared with calci-
potriol. However, no studies have been performed which
directly compare becocalcidiol with calcipotriol. Further stud-
ies are necessary to determine the role of this agent in the
management of psoriasis. It would also be interesting to test
whether increased concentrations of becocalcidiol lead to
improved therapeutic efficacy while maintaining the drug’s
favourable side-effect profile.
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